When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

BEYFORTUS is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and ...

This Tuesday, the Health Ministry will begin training medical teams ahead of a historic campaign to protect all Israeli infants against RSV.

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

Beyfortus is supplied as a 50mg/0.5mL and 100mg/mL prefilled syringe. The product is expected to be available for the upcoming 2023-2024 RSV season.

Beyfortus made $1.8 billion in sales last year, even though supplies were held back by now-resolved production constraints.

Sanofi (NASDAQ:SNY) will begin shipping Beyfortus (nirsevimab) in early Q3 to ensure widespread availability ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which typically runs ...

The CDC has announced limited availability of Sanofi immunization Beyfortus for RSV prevention in infants. Here's what parents should know to keep babies safe.

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

Despite the promise of both Beyfortus and the Pfizer RSV shot, there are obstacles to getting it to enough infants to make a dent in RSV hospitalizations this year. Timing and supply, for starters.

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.